Cargando…

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes

Anti-tumour necrosis factors (anti-TNFs) are established as first-line biological therapy for rheumatoid arthritis (RA) with over two decades of accumulated clinical experience. Anti-TNFs have well established efficacy/safety profiles along with additional benefits on various comorbidities. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Peter C., Matucci Cerinic, Marco, Alten, Rieke, Avouac, Jérôme, Westhovens, Rene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386864/ https://www.ncbi.nlm.nih.gov/pubmed/35991524 http://dx.doi.org/10.1177/1759720X221114101

Ejemplares similares

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment
por: Taylor, Peter C, et al.
Publicado: (2018)

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2020)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
por: Alten, Rieke, et al.
Publicado: (2022)

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
por: Alten, Rieke, et al.
Publicado: (2023)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
por: Hirabara, Shinya, et al.
Publicado: (2014)

Safety and efficacy of biological therapy with TNF-inhibitors and non TNF-inhibitors in a cohort of young adults affected by juvenile idiopathic arthritis (JIA): data from a single centre experience
por: Lorenzo, Ceri, et al.
Publicado: (2011)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy
por: Chen, Der-Yuan, et al.
Publicado: (2011)

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients
por: Nerviani, Alessandra, et al.
Publicado: (2020)

Physical and Emotional Burden of Rheumatoid Arthritis in Saudi Arabia: An Exploratory Cross-Sectional Study
por: Omair, Mohammed A, et al.
Publicado: (2020)

Impairment in the telocyte/CD34(+) stromal cell network in human rheumatoid arthritis synovium
por: Rosa, Irene, et al.
Publicado: (2020)

Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis
por: Taylor, Thomas R.P., et al.
Publicado: (2021)

Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques
por: Put, Stéphanie, et al.
Publicado: (2014)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

Metabolic Effects of Anti-TNF-α Treatment in Rheumatoid Arthritis
por: Macáková, Kristína, et al.
Publicado: (2023)

Arthritis after SARS-CoV-2 infection
por: Baimukhamedov, Chokan, et al.
Publicado: (2021)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017
por: Lindner, Lisa, et al.
Publicado: (2020)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
por: Genovese, Mark C, et al.
Publicado: (2014)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Publicado: (2019)

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
por: Kremer, Joel M, et al.
Publicado: (2011)

Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
por: Kaeley, Gurjit S., et al.
Publicado: (2016)

Adjustment in anti-TNF therapy after initial response: long-term follow-up in patients with rheumatoid arthritis
por: Sidiropoulos, P, et al.
Publicado: (2003)

Hepatorenal pathologies in TNF-transgenic mouse model of rheumatoid arthritis are alleviated by anti-TNF treatment
por: Li, Xuefei, et al.
Publicado: (2023)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium
por: Terenzi, Riccardo, et al.
Publicado: (2017)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Influence of anti-TNF therapy on monocyte gene expression in rheumatoid arthritis
por: Hernandez, M, et al.
Publicado: (2003)

Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalia, et al.
Publicado: (2011)

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
por: Fragoulakis, Vasilis, et al.
Publicado: (2015)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
por: Bogunia-Kubik, Katarzyna, et al.
Publicado: (2021)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
por: Matteson, Eric L., et al.
Publicado: (2023)

Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate
por: Bradford, Claire M., et al.
Publicado: (2019)

Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach
por: Alten, Rieke, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cdp2qri3m86b9q8h549atg2hj0